Keros Therapeutics (KROS) Operating Leases (2019 - 2026)

Keros Therapeutics (KROS) has reported Operating Leases for 8 consecutive years, with $13.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Leases fell 16.52% year-over-year to $13.1 million; the trailing twelve-month figure through Jun 2026 stood at $13.1 million (down 16.52% YoY), and the FY2025 full-year result was $14.5 million, down 14.26% from the prior year.
• Operating Leases declined to $13.1 million in Q2 2026 per KROS's latest filing, from $14.5 million in the prior quarter.
• Across five years, Operating Leases topped out at $19.3 million in Q3 2024 and bottomed at $12.8 million in Q4 2022.
• Historically, Operating Leases has averaged $14.7 million across 5 years, with a median of $14.2 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Operating Leases surged 5445.89% in 2022, then slipped 21.65% in 2025.
• Over 5 years, Operating Leases stood at $12.8 million in 2022, then increased by 4.9% to $13.4 million in 2023, then grew by 25.63% to $16.9 million in 2024, then retreated by 14.26% to $14.5 million in 2025, then declined by 9.31% to $13.1 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $13.1 million, $14.5 million, and $15.1 million for Q2 2026, Q4 2025, and Q3 2025 respectively.